- •Chapter 1
- •Ocular Adnexal Lymphoproliferative
- •1.1 Pathogenesis
- •1.2 Chronic Antigen Stimulation
- •1.3 Immunosuppression
- •1.4 Pathology
- •1.5 Cytogenetics
- •1.6 Clinical Features
- •1.7 Imaging Findings
- •1.8 Staging
- •1.9 Positron Emission Tomography
- •1.10 Treatment
- •1.11 Follicular Lymphoma
- •1.12 Mantle Cell Lymphoma
- •1.13 Radiotherapy
- •1.14 Chemotherapy
- •1.15 Immunotherapy
- •1.16 Radioimmunotherapy
- •1.17 Outcome
- •1.18 The Future
- •References
- •Chapter 2
- •2.1 General Introduction
- •2.2 The Aging Process and Facial Analysis
- •2.3 Endoscopic Brow Lift
- •2.3.1 Introduction
- •2.3.2 Endoscopic Browlift Anesthesia Pearls
- •2.3.4 Endoscopic Browlift Postoperative Care Pearls
- •2.4 Upper Blepharoplasty
- •2.4.1 Introduction
- •2.4.2 Patient Evaluation
- •2.4.3 Upper Blepharoplasty Anesthesia Pearls
- •2.4.4 Upper Blepharoplasty Surgical Procedure Pearls
- •2.5 Lower Blepharoplasty, Fillers, and Midface Augmentation
- •2.5.1 Introduction
- •2.5.2 Patient Evaluation
- •2.5.3 Lower Blepharoplasty Anesthesia Pearls
- •2.5.4 Lower Blepharoplasty Surgical Procedure Pearls
- •References
- •Chapter 3
- •3.1 Introduction
- •3.2 What Is the Diagnosis?
- •3.2.1 Pitfalls of Diagnosis
- •3.2.2 A Diagnostic Corticosteroid Trial?
- •3.2.3 The Question of Biopsy
- •3.3 Treatment
- •3.3.1 Corticosteroids
- •3.3.2 Radiation
- •3.3.3 Other Agents
- •3.4 Special Circumstances
- •3.4.1 Pediatric IOIS
- •3.4.2 Sclerosing Pseudotumor
- •3.4.3 Tolosa–Hunt Syndrome
- •References
- •Chapter 4
- •4.1 Introduction
- •4.2 Embryology, Anatomy, Physiology, and Pathophysiology of the Canalicular System
- •4.3 Infective Causes
- •4.3.1 Periocular Herpes Simplex Infection
- •4.3.2 Bacterial Canaliculitis
- •4.4.1 Lichen Planus
- •4.4.2 Ocular Cicatricial Pemphigoid
- •4.5 Iatrogenic Causes
- •4.5.1 Systemic Drugs
- •4.5.1.2 Docetaxel (Taxotere)
- •4.5.2 Radiotherapy
- •4.5.3 Topical Ophthalmic Treatments
- •4.5.3.2 Mitomycin C (MMC) Therapy
- •4.5.4 Lacrimal Stents and Plugs
- •4.6 The Surgical Approach to Managing Canalicular Disease
- •4.6.1 Surgical Technique for Dacryocystorhinostomy with Retrograde Canaliculostomy
- •References
- •Chapter 5
- •5.1 Introduction
- •5.2 Nomenclature
- •5.3 Clinical Manifestations of NF1
- •5.4 Orbitofacial Tumors in NF1
- •5.4.2 Malignant Peripheral Nerve Sheath Tumors
- •5.4.3 Optic Pathway Gliomas
- •5.5 Genetics
- •5.5.1 The NF1 Gene
- •5.5.2 Overlapping NF1-Like Phenotype (SPRED1)
- •5.6.1 Introduction
- •5.7 Surgical Management of Orbitofacial Tumors in NF1
- •5.7.1 Introduction
- •5.7.2 Timing of Surgery
- •5.7.3 Periorbital Involvement
- •5.7.3.1 The Upper Eyelid
- •5.7.3.2 The Lower Eyelid and Midface
- •5.7.4 Orbital Involvement
- •5.7.4.1 Proptosis
- •5.7.4.3 Proptosis Due to Optic Nerve Glioma
- •5.7.4.4 Orbital Enlargement with Dystopia and Hypoglobus
- •5.8 The Natural History of NF1 Tumor Growth from Birth to Senescence
- •References
- •Chapter 6
- •6.1 Introduction
- •6.2 Surgical Anatomy of the Lacrimal Drainage System
- •6.3 Basic Diagnostics for Disorders of the Lacrimal Drainage System
- •6.4 Selective Lacrimal Sac Biopsy in External Dacryocystorhinostomy
- •6.5.1 Case A
- •6.5.2 Case B
- •6.5.3 Case C
- •6.5.4 Case D
- •6.5.5 Case E
- •6.5.6 Case F
- •6.5.7 Case G
- •References
- •Chapter 7
- •7.1 Introduction
- •7.2 Patients and Methods
- •7.2.1 Patients
- •7.2.2 Examination
- •7.3 Results
- •7.3.1 Patient Data
- •7.3.3 Family History
- •7.3.4 Pregnancy History
- •7.3.5 Birth
- •7.3.6 Associated Systemic and Ocular Diseases
- •7.3.8 Neuroradiological Findings (Brain MRI)
- •7.3.9 Nasolacrimal System Findings
- •7.4 Discussion
- •7.4.1 Patients
- •7.4.2 Obstetric and Family History
- •7.4.3 Associated Pathologies
- •7.4.3.1 Ophthalmological Findings in Unilateral Disease
- •7.4.3.2 Neuroradiological Findings
- •7.4.3.3 Systemic Diseases
- •7.4.3.4 Nasolacrimal Duct Findings
- •7.5 Conclusions
- •References
- •Chapter 8
- •8.1 Introduction
- •8.2 Evaluation of Complicated Ptosis
- •8.2.1 Compensatory Eyebrow Elevation
- •8.2.3 Innervation Patterns of the Frontalis Muscle
- •8.2.4 Checklist of Preoperative Evaluation of Complicated Ptosis
- •8.3 Surgical Technique of Levator Muscle Recession
- •8.3.1 Principle
- •8.3.2 Approach to the Levator
- •8.3.3 Partial Levator Recession
- •8.3.4 Total Levator Recession
- •8.3.6 Undercorrection and Overcorrection
- •8.4 Surgical Technique of Brow Suspension
- •8.4.1 Materials for Brow Suspension
- •8.4.1.1 Nonautogenous Materials
- •8.4.1.2 Autogenous Fascia Lata
- •8.4.2 Our Technique of Harvesting Autogenous Fascia Lata
- •8.4.3 Mechanical Principals of Brow Suspension
- •8.4.4 Upper Lid Approach
- •8.4.5 Fascia Implantation
- •References
- •Chapter 9
- •Modern Concepts in Orbital Imaging
- •9.1 Computerized Tomography
- •9.2 Three-Dimensional Imaging
- •9.3 Magnetic Resonance Imaging
- •9.3.1 The T1 Constant
- •9.3.2 The T2 Constant
- •9.3.3 Creating the MR Image
- •9.4 Imaging of Common Orbital Lesions
- •9.4.1 Adenoid Cystic Carcinoma
- •9.4.2 Cavernous Hemangioma
- •9.4.3 Dermoid Cyst
- •9.4.4 Fibrous Dysplasia
- •9.4.5 Lymphangioma
- •9.4.6 Lymphoma
- •9.4.7 Myositis
- •9.4.8 Optic Nerve Glioma
- •9.4.9 Pseudotumor
- •9.4.10 Rhabdomyosarcoma
- •9.6 Positron Emission Tomography
- •9.7 Orbital Ultrasound
- •9.7.1 Physics and Instrumentation
- •9.7.1.1 Topographic Echography
- •9.7.1.2 Quantitative Echography
- •9.7.1.3 Kinetic Echography
- •9.7.2 Extraocular Muscles
- •9.7.3 Optic Nerves
- •References
- •Chapter 10
- •10.1 Introduction
- •10.3 Etiology
- •10.4 Microbiology
- •10.5 Changing Pathogens and Resistance
- •10.5.2 Orbital MRSA
- •10.6 Evaluation of Orbital Cellulitis
- •10.7 Medical Treatment of Orbital Cellulitis
- •10.8 Surgical Treatment of Orbital Cellulitis
- •10.9 Prevention of Orbital Cellulitis After Orbital Fracture
- •References
- •Chapter 11
- •11.1 Clinical Picture
- •11.1.1 Clinical Phases
- •11.2 Ocular Complications
- •11.3 Investigation
- •11.3.1 Angiography
- •11.4 Management
- •11.4.1 Active Nonintervention
- •11.4.2 Indications for Treatment
- •11.5 Modalities of Treatment
- •11.5.1 Steroids
- •11.5.1.1 Topical Steroids
- •11.5.1.2 Intralesional Corticosteroid Injection
- •11.5.1.3 Oral Corticosteroids
- •11.5.2 Interferon-Alfa
- •11.5.3 Vincristine
- •11.5.4 Laser
- •11.5.5 Embolization
- •11.5.6 Surgery
- •References
- •Chapter 12
- •12.1 Introduction
- •12.2 Epidemiology
- •12.3 Biological Behavior and Timing of Metastasis
- •12.4 Lateralization
- •12.5 Localization
- •12.6 Clinical Features
- •12.7 Imaging and Patterns of Orbital Metastatic Disease
- •12.8 Biopsy
- •12.9 Common Types of Orbital Metastases
- •12.9.1 Breast Carcinoma
- •12.9.2 Lung Carcinoma
- •12.9.3 Prostatic Cancer
- •12.9.4 Melanoma
- •12.9.5 Carcinoid Tumor
- •12.11 Treatment
- •12.11.1 Radiotherapy
- •12.11.2 Chemotherapy
- •12.11.3 Hormonal Therapy
- •12.11.4 Surgery
- •12.12 Prognosis and Survival
- •References
- •Chapter 13
- •13.1 Introduction
- •13.2 Rituximab
- •13.3 Yttrium-90-Labeled Ibritumomab Tiuxetan
- •13.4 Imatinib Mesylate
- •13.5 Cetuximab
- •References
- •Chapter 14
- •14.1 Introduction
- •14.2 Porous Orbital Implants
- •14.3 Orbital Implant Selection in Adults
- •14.4 Orbital Implant Selection in Children
- •14.5 Volume Considerations in Orbital Implant Selection
- •14.7 Which Wrap to Use
- •14.8 To Peg or Not to Peg Porous Implants
- •14.9 Summary
- •References
- •Chapter 15
- •15.1 Introduction
- •15.2 Etiology and Presentation
- •15.2.1 Etiology of Orbital Volume Loss
- •15.2.2 Etiology of Periorbital Volume Loss
- •15.2.3 Features of Orbital Volume Loss
- •15.2.4 Features of Periorbital Volume Loss
- •15.3 Background to Injectable Soft-Tissue Fillers
- •15.3.1 Historical Perspective on Volume Replacement
- •15.4 Types of Injectable Soft-Tissue Filler
- •15.4.1 Collagen Fillers
- •15.4.2 Hyaluronic acid Fillers
- •15.5 Treatment Areas
- •15.5.1 Orbit
- •15.5.2 Upper Eyelid and Brow
- •15.5.3 Tear Trough
- •15.5.4 Temple and Brow
- •15.6 Other Periorbital Uses of Injectable Soft-Tissue Fillers
- •15.6.1 Upper Eyelid Loading
- •15.6.2 Lower Eyelid Elevation
- •15.6.3 Treatment of Cicatricial Ectropion
- •15.7 Future Developments
- •References
170 |
11 Current Concepts in the Management of Infantile Hemangiomas |
References
1.Aldave AJ, Shields CL, Shields JA (1999 Nov–Dec) Surgical excision of selected amblyogenic periorbital capillary
11 |
hemangiomas. Ophthalmic Surg Lasers 30:754–757 |
2.Ashino R, Geronemus RG (1993 Mar) Failure of the flashlamp-pumped pulsed dye laser to prevent progression to deep hemangioma. Pediatr Dermatol 10:77–80
3.Baker LL, Dillon WP, Hieshima GB, Dowd CF, Frieden IJ (1993 Mar–Apr) Hemangiomas and vascular malformations of the head and neck: MR characterization. AJNR Am J Neuroradiol 14:307–314
4.Barlow CF,Priebe CJ,Mulliken JB,Barnes PD,Mac Donald D, Folkman J, Ezekowitz RA (1998 Mar) Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 132:527–530
5.Batta K, Goodyear HM, Moss C, Williams HC Hiller L, Waters R (2002 Aug 17) Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet 360:521–527
6.Bennett ML, Fleischer AB, Jr., Chamlin SL, Frieden IJ (2001 Sept) Oral corticosteroid use is e ective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 137:1208–1213
7.Bruckner AL, Frieden IJ (2003 Apr) Hemangiomas of infancy. J Am Acad Dermatol 48:477–493; quiz 494–476
8.Bruckner AL, Frieden IJ (2006 Oct) Infantile hemangiomas. J Am Acad Dermatol 55:671–682
9.Ceisler EJ, Santos L, Blei F (2004 Jan–Feb) Periocular hemangiomas: what every physician should know. Pediatr Dermatol 21:1–9
10.Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, Nopper AJ, Frieden IJ (2008 Aug) Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 122:360–367
11.Dubois J, Garel L (1999 Dec) Imaging and therapeutic approach of hemangiomas and vascular malformations in the pediatric age group. Pediatr Radiol 29:879–893
12.Dubois J, Milot J, Jaeger BI, McCuaig C, Rousseau E, Powell J (2006 Oct) Orbit and eyelid hemangiomas: is there a relationship between location and ocular problems?. J Am Acad Dermatol 55:614–619
13.Dubois J, Patriquin HB, Garel L, Powell J, Filiatrault D, David M, Grignon A (1998 July) Soft-tissue hemangiomas in infants and children: diagnosis using Doppler sonography. AJR Am J Roentgenol 171:247–252
14.Egbert JE, Paul S, Engel WK, Summers CG (2001 May) High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas. Arch Ophthalmol 119:677–683
15.Ezekowitz RA, Mulliken JB, Folkman J (1992 May 28) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326:1456–1463
16.Fawcett SL, Grant I, Hall PN, Kelsall AW, Nicholson JC (2004 Mar) Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 57: 168–171
17.Frieden IJ, Reese V, Cohen D (1996 Mar) PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 132:307–311
18.Garzon MC, Lucky AW, Hawrot A, Frieden IJ (2006 Feb) Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 52:281–286
19.Geh JL, Geh VS, Jemec B, Liasis A, Harper J, Nischal KK, Dunaway D (2007 Apr 15) Surgical treatment of periocular hemangiomas: a single-center experience. Plast Reconstr Surg 119:1553–1562
20.George ME, Sharma V, Jacobson J, Simon S, Nopper AJ (2004 Aug) Adverse e ects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 140:963–969
21.Haggstrom AN, Lammer EJ, Schneider RA, Marcucio R, Frieden IJ (2006 Mar) Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 117:698–703
22.Haik BG, Jakobiec FA, Ellsworth RM, Jones IS (1979 May) Capillary hemangioma of the lids and orbit: an analysis of the clinical features and therapeutic results in 101 cases. Ophthalmology 86:760–792
23.Halliday HL, Ehrenkranz RA, Doyle LW (2003) Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 1:CD001145
24.Halliday HL, Ehrenkranz RA, Doyle LW (2003) Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1:CD001146
25.Halliday HL, Ehrenkranz RA, Doyle LW (2003) Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.Cochrane Database Syst Rev 1:CD001144
26.Kolde G (2003 Jan 25) Early pulsed-dye laser treatment of childhood haemangiomas. Lancet 361:348–349; author reply 349
27.Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A (2008 June 12) Propranolol for severe hemangiomas of infancy. N Engl J Med 358: 2649–2651
28.Leaute-Labreze C, Taieb A (2008 Dec) E cacy of betablockers in infantile capillary haemangiomas: the
References 171
physiopathological significance and therapeutic consequences. Ann Dermatol Venereol 135:860–862
29.Levi M, Schwartz S, Blei F, Ceisler E, Steele M, Furlan L, Millman A, Kodsi SR (June 2007) Surgical treatment of capillary hemangiomas causing amblyopia. J AAPOS 11: 230–234
30.Metry DW, Dowd CF, Barkovich AJ, Frieden IJ (2001 July) The many faces of PHACE syndrome. J Pediatr 139: 117–123
31.Metry DW, Dowd CF, Barkovich AJ, Frieden IJ (2001 July) The many faces of PHACE syndrome. J Pediatr 139:117–123
32.Metry DW, Hebert AA (2000 July) Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol 136:905–914
33.Mulliken JB, Rogers GF, Marler JJ (2002 Apr 15) Circular excision of hemangioma and purse-string closure: the smallest possible scar. Plast Reconstr Surg 109:1544–1554; discussion 1555
34.North PE, Mizeracki A, Mihm MC, Jr., Mrak RE (2000 May–June) GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma. Clin Neuropathol 19:131–137
35.North PE,Waner M, Buckmiller L, James CA, Mihm MC Jr (2006 Nov–Dec) Vascular tumors of infancy and childhood: beyond capillary hemangioma. Cardiovasc Pathol 15:303–317
36.North PE, Waner M, Mizeracki A, Mrak RE, Nicholas R, Kincannon J, Suen JY, Mihm MC, Jr (2001 May) A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 137:559–570
37.Perez J, Pardo J, Gomez C (2002) Vincristine—an e ective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol 41:197–199
38.Ricketts RR, Hatley RM, Corden BJ, Sabio H, Howell CG (1994 June) Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg 219:605–612; discussion 612–604
39.Ritter MR, Butschek RA, Friedlander M, Friedlander SF (2007) Pathogenesis of infantile haemangioma: new molecular and cellular insights. Expert Rev Mol Med 9:1–19
40.Schwartz SR, Blei F, Ceisler E, Steele M, Furlan L, Kodsi S (June 2006) Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. J AAPOS 10:262–268
41.Shorr N, Sei SR (1986 Apr) Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 17:229–231
42.Stigmar G, Crawford JS, Ward CM, Thomson HG (1978 June) Ophthalmic sequelae of infantile hemangiomas of the eyelids and orbit. Am J Ophthalmol 85:806–813
43.Weiss AH, Kelly JP (2008 Feb) Reappraisal of astigmatism induced by periocular capillary hemangioma and treatment with intralesional corticosteroid injection. Ophthalmology 115:390–397.e391
44.Whiteman DW, Rosen DA, Pinkerton RM (1980 June) Retinal and choroidal microvascular embolism after intranasal corticosteroid injection.Am J Ophthalmol 89:851–853
45.Witman PM, Wagner AM, Scherer K, Waner M, Frieden IJ (2006 Feb) Complications following pulsed dye laser treatment of superficial hemangiomas. Lasers Surg Med 38: 116–123
46.Yagci A, Palamar M, Egrilmez S, Sahbazov C, Ozbek SS (2008 Jan–Feb) Anterior segment ischemia and retinochoroidal vascular occlusion after intralesional steroid injection. Ophthal Plast Reconstr Surg 24:55–57
